

**WELIREG
(belzutifan)**

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Von Hippel-Lindau (VHL) disease
 - a. 18 years of age or older
 - b. Patient has **ONE** of the following:
 - i. Renal cell carcinoma (RCC)
 - ii. Central nervous system (CNS) hemangioblastomas
 - iii. Pancreatic neuroendocrine tumors (pNET)
 - c. Patient does not require immediate surgery
2. Advanced renal cell carcinoma (RCC)
 - a. 18 years of age or older
 - b. Previous treatment with **ALL** of the following:
 - i. PD-1 inhibitor **OR** PD-L1 inhibitor
 - ii. VEGF-TKI
3. Locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL)
 - a. 12 years of age or older

AND ALL of the following:

1. Hemoglobin ≥ 8 g/dL
2. Prescriber agrees to monitor for anemia and hypoxia before initiation of treatment and periodically throughout treatment
3. Females of reproductive potential **only**: patient has had a negative pregnancy test **AND** patient will be advised to use effective non-hormonal contraception during treatment with Welireg and for 1 week after the last dose
4. Males with female partners of reproductive potential **only**: pregnancy will be excluded before start of treatment and patient will be advised to use effective non-hormonal contraception during treatment with Welireg and for 1 week after the last dose

Prior - Approval Limits

Quantity 120 mg per day



**WELIREG
(belzutifan)**

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Von Hippel-Lindau (VHL) disease
 - a. 18 years of age or older
 - b. Patient has **ONE** of the following:
 - i. Renal cell carcinoma (RCC)
 - ii. Central nervous system (CNS) hemangioblastomas
 - iii. Pancreatic neuroendocrine tumors (pNET)
 - c. Patient does not require immediate surgery
2. Advanced renal cell carcinoma (RCC)
 - a. 18 years of age or older
3. Advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL)
 - a. 12 years of age or older

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Hemoglobin ≥ 8 g/dL
3. Prescriber agrees to monitor for anemia and hypoxia periodically throughout treatment
4. Females of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Welireg and for 1 week after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Welireg and for 1 week after the last dose

Prior - Approval *Renewal* Limits

Same as above